Burnett Patrick 4
4 · Arcutis Biotherapeutics, Inc. · Filed Nov 10, 2025
Insider Transaction Report
Form 4
Burnett Patrick
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-11-06$3.64/sh+17,250$62,790→ 115,575 total - Exercise/Conversion
Stock Option (right to buy)
2025-11-06−17,250→ 155,250 totalExercise: $3.64Exp: 2034-01-12→ Common Stock (17,250 underlying) - Sale
Common Stock
2025-11-06$24.18/sh−17,250$417,145→ 98,325 total
Footnotes (3)
- [F1]The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026.
- [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.79 to $24.4493, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]On January 12, 2024, the Reporting Person was granted options, in which 1/48th of the shares subject to the option vest on each monthly anniversary measured from January 12, 2024 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer.